Nevertheless, our results suggest that miR-644a or its target CTBP1 could be a potential drug candidate which can simultaneously block primary tumor growth, metastasis, and finally sensitize cancer cells to several different drugs. This evidence concerns the gene CTBP1 and neoplasm.